Changes of lysozyme content in the lacrimal fluid in patients with diabetic retinopathy (pilot study)
https://doi.org/10.29413/ABS.2022-7.1.7
Abstract
Background. Type 2 diabetes mellitus is one of the most common metabolic disorders in humans. Diabetes mellitus can lead to abnormalities in many tissues of the eye structure, exposing patients to the risk of developing a wide range of ocular pathologies associated with changes in its anterior and posterior segments. The most common complication is diabetic retinopathy.
The aim: to assess the potential clinical significance of lacrimal lysozyme as a minimally invasive biomarker of diabetic ophthalmic disorders.
Material and methods. Three groups were formed during the study. Group 1 (Control, n = 10) included conditionally healthy people with no type 2 diabetes mellitus. Group 2 (Main 1, n = 15) included patients with type 2 diabetes mellitus, but no diabetic manifestations in the fundus. Group 3 (Main 2, n = 15) included patients with type 2 diabetes mellitus and manifestations of diabetic retinopathy of varying degrees. In patients of all groups, the level of tear lysozyme was assessed.
Results. It was found that the concentration of lacrimal fluid lysozyme in patients with type 2 diabetes mellitus was significantly lower than in healthy patients. In patients with diabetic retinopathy of varying degrees of manifestation (non-proliferative and proliferative forms) against the background of type 2 diabetes mellitus, significantly lower values of lysozyme were observed compared to patients with type 2 diabetes mellitus, but without diabetic ophthalmic manifestations.
Conclusion. It is possible that local detection of lysozyme in the lacrimal fluid may be potential biomarkers of the progression of diabetic retinopathy.
About the Authors
A. D. Chuprov
Orenburg Branch of S. Fyodorov Eye Microsurgery Federal State Institution
Russian Federation
Russian Federation
Dr. Sc. (Med.), Professor, Director,
Salmyshskaya str. 17, Orenburg 460047
A. N. Kazennov
Orenburg Branch of S. Fyodorov Eye Microsurgery Federal State Institution
Russian Federation
Russian Federation
Head of the Surgery Block,
Salmyshskaya str. 17, Orenburg 460047
O. V. Marshinskaya
Federal Research Centre of Biological Systems and Agrotechnologies of the Russian Academy of Sciences;
Orenburg State University, Institute of Bioelementology
Russian Federation
Russian Federation
Junior Research Officer, 9-go Yanvarya str. 29, Orenburg 460000;
Junior Research Officer, Institute of Bioelementology, Pobedy ave. 13, Orenburg 460018
T. V. Kazakova
Federal Research Centre of Biological Systems and Agrotechnologies of the Russian Academy of Sciences;
Orenburg State University, Institute of Bioelementology
Russian Federation
Russian Federation
Junior Research Officer, 9-go Yanvarya str. 29, Orenburg 460000;
Junior Research Officer, Institute of Bioelementology, Pobedy ave. 13, Orenburg 460018
References
1. Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature. 2019; 576(7785): 51-60. doi: 10.1038/s41586-019-1797-8
2. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020; 21(17): 6275. doi: 10.3390/ijms21176275
3. Shih KC, Lam KS, Tong L. A systematic review on the impact of diabetes mellitus on the ocular surface. Nutr Diabetes. 2017; 7(3): e251. doi: 10.1038/nutd.2017.4
4. Browning DJ, Stewart MW, Lee C. Diabetic macular edema: Evidence-based management. Indian J Ophthalmol. 2018; 66(12): 1736-1750. doi: 10.4103/ijo.IJO_1240_18
5. Simó-Servat O, Hernández C, Simó R. Diabetic retinopathy in the context of patients with diabetes. Ophthalmic Res. 2019; 62(4): 211-217. doi: 10.1159/000499541
6. Kiziltoprak H, Tekin K, Inanc M, Goker YS. Cataract in diabetes mellitus. World J Diabetes. 2019; 10(3): 140-153. doi: 10.4239/wjd.v10.i3.140
7. Skarbez K, Priestley Y, Hoepf M, Koevary SB. Comprehensive review of the effects of diabetes on ocular health. Expert Rev Ophthalmol. 2010; 5(4): 557-577. doi: 10.1586/eop.10.44
8. Markan A, Agarwal A, Arora A, Bazgain K, Rana V, Gupta V. Novel imaging biomarkers in diabetic retinopathy and diabetic macular edema. Ther Adv Ophthalmol. 2020; 12: 2515841420950513. doi: 10.1177/2515841420950513
9. Chawla R, Nair S, Venkatesh P, Garg S, Mittal K. Bilateral disc drusen in a diabetic patient simulating diabetic papillopathy as a cause of disc edema. Indian J Ophthalmol. 2017; 65(10): 1051-1053. doi: 10.4103/ijo.IJO_355_17
10. Misra SL, Braatvedt GD, Patel DV. The impact of diabetes mellitus on the ocular surface: A review. Clin Exp Ophthalmol. 2016; 44(4): 278-288. doi: 10.1111/ceo.12690
11. Song BJ, Aiello LP, Pasquale LR. Presence and risk factors for glaucoma in patients with diabetes. Curr Diab Rep. 2016; 16(12): 124. doi: 10.1007/s11892-016-0815-6
12. Lechner J, O’Leary OE, Stitt AW. The pathology associated with diabetic retinopathy. Vision Res. 2017; 139: 7-14. doi: 10.1016/j.visres.2017.04.003
13. Altmann C, Schmidt MHH. The role of microglia in diabetic retinopathy: Inflammation, microvasculature defects and neurodegeneration. Int J Mol Sci. 2018; 19(1): 110. doi: 10.3390/ijms19010110
14. Garg S, Davis RM. Diabetic retinopathy screening update. Clinical Diabetes Fall. 2009; 27(4): 140-145. doi: 10.2337/diaclin.27.4.140
15. Mozherenkov VP, Prokof’eva GL, Usova LA. Ocular manifestations of diabetes mellitus. Russian Journal of Clinical Ophthalmology. 2002; 1: 31. (In Russ.).
16. Saari KM, Aine E, Posz A, Klockars M. Lysozyme content of tears in normal subjects and in patients with external eye infections. Graefes Arch Clin Exp Ophthalmol. 1983; 221(2): 86-88. doi: 10.1007/BF02133813
17. Hagan S, Martin E, Enríquez-de-Salamanca A. Tear fluid biomarkers in ocular and systemic disease: Potential use for predictive, preventive and personalised medicine. EPMA J. 2016; 7(1): 15. doi: 10.1186/s13167-016-0065-3
18. You J, Willcox MD, Madigan MC, Wasinger V, Schiller B, Walsh BJ, et al. Tear fluid protein biomarkers. Adv Clin Chem. 2013; 62: 151-196. doi: 10.1016/b978-0-12-800096-0.00004-4
19. Hanstock HG, Edwards JP, Walsh NP. Tear lactoferrin and lysozyme as clinically relevant biomarkers of mucosal immune competence. Front Immunol. 2019; 10: 1178. doi: 10.3389/fimmu.2019.01178
20. Moll A, Wyka K, Młynarski W, Niwald A. Level of selected antibacterial tear proteins in children with diabetes type 1. Klin Oczna. 2011; 113(10-12): 336-340.
21. Bukharin OV, Valyshev AV, Elagina NN, Ivanov YuB, Cherkasov SV. Method for determining antilysozyme activity of microorganisms: Patent N 2126051 of the Russian Federation. 1999. (In Russ.).
22. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010; 33(11): 2399-2405. doi: 10.2337/dc10-0493
23. Osaadon P, Fagan XJ, Lifshitz T, Levy J. A review of antiVEGF agents for proliferative diabetic retinopathy. Eye (Lond). 2014; 28(5): 510-520. doi: 10.1038/eye.2014.13
24. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: A systematic review. JAMA. 2007; 298(8): 902-916. doi: 10.1001/jama.298.8.902
25. Koss MJ, Naser H, Sener A, Ackermann H, Al-Sarireh F, Singh P, et al. Combination therapy in diabetic macular oedema and retinal vein occlusion – past and present. Acta Ophthalmol. 2012; 90(6): 580-589. doi: 10.1111/j.1755-3768.2010.01962.x
26. Nguyen-Khuong T, Everest-Dass AV, Kautto L, Zhao Z, Willcox MDP, Packer NH. Glycomic characterization of basal tears and changes with diabetes and diabetic retinopathy. Glycobiology. 2015; 25(3): 269-283. doi: 10.1093/glycob/cwu108
27. Herber S, Grus FH, Sabuncuo P, Augustin AJ. Two-dimensional analysis of tear protein patterns of diabetic patients. Electrophoresis. 2001; 22(9): 1838-1844. doi: 10.1002/1522-2683(200105)22:93.0.CO;2-7
28. El-Asrar AM. Role of inflammation in the pathogenesis of diabetic retinopathy. Middle East Afr J Ophthalmol. 2012; 19(1): 70-74. doi: 10.4103/0974-9233.92118
29. Balaiya S, Zhou Z, Chalam KV. Characterization of vitreous and aqueous proteome in humans with proliferative diabetic retinopathy and its clinical correlation. Proteomics Insights. 2017; 8(1): 1178641816686078. doi: 10.1177/1178641816686078
30. Fullard RJ, Snyder C. Protein levels in nonstimulated and stimulated tears of normal human subjects. Invest Ophthalmol Vis Sci. 1990; 31: 1119-1126.
31. Fullard RJ, Tucker DL. Changes in human tear protein levels with progressively increasing stimulus. Investig Ophthalmol Vis Sci. 1991; 32: 2290-2301.
32. Sen DK, Sarin GS. Biological variations of lysozyme concentration in the tear fluids of healthy persons. Br J Ophthalmol. 1986; 70(4): 246-248. doi: 10.1136/bjo.70.4.246
33. McGill JI, Liakos GM, Goulding N, Seal V. Normal tear protein profiles and age-related changes. Br J Ophthalmol. 1984; 68(5): 316-320. doi: 10.1136/bjo.68.5.316
34. Csősz E, Boross P, Csutak A, Berta A, Tóth F, Póliska S, et al. Quantitativыe analysis of proteins in the tear fluid of patients with diabetic retinopathy. J Proteomics. 2012; 75(7): 2196-2204. doi: 10.1016/j.jprot.2012.01.019
Review
For citations:
Chuprov A.D., Kazennov A.N., Marshinskaya O.V., Kazakova T.V. Changes of lysozyme content in the lacrimal fluid in patients with diabetic retinopathy (pilot study). Acta Biomedica Scientifica. 2022;7(1):59-66. (In Russ.) https://doi.org/10.29413/ABS.2022-7.1.7
Views:
931
Email this article 
